Immunoglobulin Fc-Fusion Proteins

Over the past decades, several monoclonal antibodies (MAbs) and MAb-derivative products have been approved for therapeutic use in the United States. Specifically, one class of antibody derivatives has acquired growing importance: Fc-fusion proteins.

The interest in Fc-fusion proteins lies in the fact that the potential therapeutic value of many proteins — including enzymes, receptors, cytokines, blood factors, and peptides — can be realized by fusing them to the Fc region of human immunoglobulin G.

Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing process and therapeutic uses:

• Article “Immunoglobulin Fc-Fusion Proteins Part 1: Their Design and Manufacture”
• Article “Immunoglobulin Fc-Fusion Proteins Part 2: Therapeutic Uses and Clinical Development”

Our experts behind the articles:

• Angela Linderholm
• Steven M. Chamow

Contact us to discover how our team’s comprehensive knowledge in biologics, MAbs, and Mab-derivative products can make a significant difference in your development journey.